Bayer’s Legal Victory Clears the Decks for a Pipeline Showdown

Bayer has pulled off a rare double: a landmark Supreme Court win that extinguishes thousands of Roundup lawsuits and a pharmaceutical pipeline that finally looks ready to fill the revenue hole left by Xarelto’s patent cliff. Investors have responded with a 34.19% rally over the past 30 days, pushing the stock to €47.22. But behind the euphoria lies a delicate balancing act between billions in settlement costs, a tightly wound balance sheet, and the make-or-break approval of a stroke drug.

The US Supreme Court’s 7-2 ruling on Monday gave Bayer an almost complete legal victory. The justices ruled that federal law trumps state-level warning requirements for glyphosate, effectively gutting the “failure-to-warn” claims that had fueled tens of thousands of lawsuits. Bayer responded by offering a fresh $7.25 billion settlement to resolve remaining cases, on top of the more than $10 billion already paid out globally. The stock jumped nearly 19% in the week following the verdict, closing at €45.86 on Monday.

That surge has pushed the Relative Strength Index to 78.5, well above the 70 threshold that signals an overbought condition. Just a week earlier the RSI stood at 76.2, and the annual volatility of roughly 58% underscores the market’s lingering jitters. Technically, the stock now trades about 24% above its 50-day moving average, leaving it vulnerable to a short-term pullback if no fresh catalysts emerge.

Should investors sell immediately? Or is it worth buying Bayer?

With the legal cloud finally thinning, attention is shifting squarely to Bayer’s drug pipeline. The most critical asset is Asundexian, an experimental stroke prevention drug that is under regulatory review in the US, Europe, and Japan. The FDA has granted priority review, potentially cutting the decision timeline from ten months to six, and plans to rule by the end of 2026. If approved, Asundexian would become the first European FXIa inhibitor, giving Bayer a head start over competitors. Analysts project annual sales in the billions.

The drug has a checkered past, however. It failed in a 2023 trial for patients with atrial fibrillation and only proved effective in secondary stroke prevention. Regulators and investors will scrutinise the Phase III data closely. At the same time, Bayer completed its acquisition of Perfuse Therapeutics on 17 June 2026, securing full rights to PER-001, an eye implant in Phase II that showed early promise — 37.5% of high-dose patients saw significant visual field improvements versus none in the control group. But a potential approval is still years away.

All of this comes against a backdrop of intense financial pressure. Bayer has trimmed net debt to just under €30 billion, but expects cash outflows of roughly €5 billion in 2026 for legal settlements alone. That leaves little room for error. The company has already cut costs by €1.5 billion over the past two years, and management is targeting mid-single-digit pharmaceutical growth from 2027 and an operating margin of around 30% by 2030. Cash flow will be the key metric when Bayer reports quarterly results in August.

For now, the Asundexian FDA decision remains the single most important catalyst. If approval comes through, the stock could undergo a structural revaluation. If the cash squeeze becomes too tight or the pipeline disappoints, the current rally could unravel quickly. As one analyst put it, the legal victory buys Bayer time — but the clock is still ticking on the science.

Ad

Bayer Stock: New Analysis - 30 June

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYER’S | boerse | 69662225 |